11571

    543635

    PPLPHARMA

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    PIRAMAL PHARMA LIMITED Share Price Today

    PIRAMAL PHARMA LIMITED is currently trading at ₹168.58, up by ₹0.49 from the previous close. The stock touched an intraday high of ₹173.10 and a low of ₹168.01 during the latest trading session. Over the past one year, PIRAMAL PHARMA LIMITED has delivered a loss of 18.02%, while the stock has declined 3.51% in the last one month.

    PIRAMAL PHARMA LIMITED performance

    Today’s low Today’s high
    ₹ 168.01 ₹ 173.10
    ₹ 168.09
    52 week low 52 week high
    ₹ 132.30 ₹ 220.85
    ₹ 168.09
    Open Price ₹ 168.68
    Prev. Close ₹ 168.09
    Volume (Shares) 4054434.00
    Total traded value ₹ 6815.09
    Upper Circuit ₹ 201.70
    Lower Circuit ₹ 134.48
    info

    Investment Returns

    Over 1 Month -3.51% Over 3 Months 22.10% Over 6 Months -3.54% Over 1 Year -18.02%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    PIRAMAL PHARMA LIMITED fundamentals


    • Market cap (Cr) 22,378.60
    • P/E Ratio (TTM) 31.68
    • Beta 1.15
    • Book Value / share 61.18
    • Return on equity 9.76%
    • EPS (TTM) 5.81
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 261.63
    info icon alternate text
    • Market cap (Cr) 22,393.30
    • P/E Ratio (TTM) 31.68
    • Beta 1.01
    • Book Value / share 61.18
    • Return on equity 9.76%
    • EPS (TTM) 5.81
    • Dividend yield 0.00%
    • Net profit/quarter (Cr) 261.63
    info icon alternate text

    PIRAMAL PHARMA LIMITED Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 1489.06
    Operating Expense 1275.33
    Net Profit 261.63
    Net Profit Margin (%) 17.57
    Earnings Per Share (EPS) 1.97
    EBITDA 421.47
    Effective Tax Rate (%) 21.16
    Particulars DEC 2025 (Values in Cr)
    Revenue 1195.81
    Operating Expense 1110.09
    Net Profit 128.91
    Net Profit Margin (%) 10.78
    Earnings Per Share (EPS) 0.97
    EBITDA 236.46
    Effective Tax Rate (%) 16.79
    Particulars SEP 2025 (Values in Cr)
    Revenue 1127.26
    Operating Expense 1081.82
    Net Profit 196.33
    Net Profit Margin (%) 17.41
    Earnings Per Share (EPS) 1.48
    EBITDA 329.04
    Effective Tax Rate (%) 20.64
    Particulars JUN 2025 (Values in Cr)
    Revenue 969.88
    Operating Expense 1008.22
    Net Profit 113.14
    Net Profit Margin (%) 11.66
    Earnings Per Share (EPS) 0.85
    EBITDA 225.25
    Effective Tax Rate (%) 20.64
    Particulars MAR 2025 (Values in Cr)
    Revenue 1689.80
    Operating Expense 1364.95
    Net Profit 277.27
    Net Profit Margin (%) 16.40
    Earnings Per Share (EPS) 2.09
    EBITDA 456.09
    Effective Tax Rate (%) 23.90
    Particulars MAR 2026 (Values in Cr)
    Revenue 4782.01
    Operating Expense 4475.46
    Net Profit 700.01
    Net Profit Margin (%) 14.63
    Earnings Per Share (EPS) 5.28
    EBITDA 1212.22
    Effective Tax Rate (%) 20.16
    Particulars MAR 2025 (Values in Cr)
    Revenue 5285.71
    Operating Expense 4581.92
    Net Profit 691.40
    Net Profit Margin (%) 13.08
    Earnings Per Share (EPS) 5.22
    EBITDA 1247.79
    Effective Tax Rate (%) 24.11
    Particulars MAR 2024 (Values in Cr)
    Revenue 4390.11
    Operating Expense 4084.54
    Net Profit 391.22
    Net Profit Margin (%) 8.91
    Earnings Per Share (EPS) 3.05
    EBITDA 819.98
    Effective Tax Rate (%) 22.93
    Particulars MAR 2023 (Values in Cr)
    Revenue 3443.22
    Operating Expense 3653.64
    Net Profit 69.50
    Net Profit Margin (%) 2.01
    Earnings Per Share (EPS) 0.58
    EBITDA 431.64
    Effective Tax Rate (%) 43.81
    Particulars MAR 2022 (Values in Cr)
    Revenue 3340.42
    Operating Expense 3087.80
    Net Profit 367.54
    Net Profit Margin (%) 11.00
    Earnings Per Share (EPS) 3.12
    EBITDA 684.99
    Effective Tax Rate (%) 20.50
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 61.35
    ROE % 1.14
    ROCE % 6.43
    Total Debt to Total Equity 0.60
    EBITDA Margin 18.06
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 59.80
    ROE % 0.22
    ROCE % 5.40
    Total Debt to Total Equity 0.70
    EBITDA Margin 17.47
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 56.76
    ROE % -2.77
    ROCE % 1.90
    Total Debt to Total Equity 0.72
    EBITDA Margin 12.72
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 56.47
    ROE % 6.11
    ROCE % 6.91
    Total Debt to Total Equity 0.58
    EBITDA Margin 19.35
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 56.35
    ROE % 14.90
    ROCE % 12.67
    Total Debt to Total Equity 0.54
    EBITDA Margin 26.25
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 56.27
    ROE % 9.76
    ROCE % 12.31
    Total Debt to Total Equity 0.17
    EBITDA Margin 23.61
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 50.74
    ROE % 6.53
    ROCE % 8.27
    Total Debt to Total Equity 0.24
    EBITDA Margin 18.68
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 44.09
    ROE % 1.34
    ROCE % 3.62
    Total Debt to Total Equity 0.27
    EBITDA Margin 12.54
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 43.20
    ROE % 7.97
    ROCE % 9.82
    Total Debt to Total Equity 0.15
    EBITDA Margin 20.51
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 41.23
    ROE % 13.94
    ROCE % 16.15
    Total Debt to Total Equity 0.04
    EBITDA Margin 28.42
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 501.46
    Total Assets 15677.59
    Total Liabilities 15677.59
    Total Equity 8125.47
    Share Outstanding 132
    Price to Book Ratio 3.99
    Return on Assets (%) 0.58
    Return on Capital (%) 0.71
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 482.56
    Total Assets 15311.81
    Total Liabilities 15311.81
    Total Equity 7911.37
    Share Outstanding 132
    Price to Book Ratio 2.54
    Return on Assets (%) 0.11
    Return on Capital (%) 0.14
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 307.56
    Total Assets 14522.56
    Total Liabilities 14522.56
    Total Equity 6773.50
    Share Outstanding 119
    Price to Book Ratio 1.55
    Return on Assets (%) -1.28
    Return on Capital (%) -1.52
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 328.99
    Total Assets 12797.04
    Total Liabilities 12797.04
    Total Equity 6696.60
    Share Outstanding 118
    Price to Book Ratio 0.00
    Return on Assets (%) 2.93
    Return on Capital (%) 3.51
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 405.62
    Total Assets 10899.78
    Total Liabilities 10899.78
    Total Equity 5605.00
    Share Outstanding 99
    Price to Book Ratio 0.00
    Return on Assets (%) 7.66
    Return on Capital (%) 9.81
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 177.84
    Total Assets 10391.83
    Total Liabilities 10391.83
    Total Equity 7452.54
    Share Outstanding 132
    Price to Book Ratio 3.99
    Return on Assets (%) 6.65
    Return on Capital (%) 7.97
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 241.73
    Total Assets 9550.88
    Total Liabilities 9550.88
    Total Equity 6712.07
    Share Outstanding 132
    Price to Book Ratio 2.54
    Return on Assets (%) 4.09
    Return on Capital (%) 4.97
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 64.16
    Total Assets 8042.40
    Total Liabilities 8042.40
    Total Equity 5261.79
    Share Outstanding 119
    Price to Book Ratio 1.55
    Return on Assets (%) 0.86
    Return on Capital (%) 1.01
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 137.23
    Total Assets 7371.04
    Total Liabilities 7371.04
    Total Equity 5123.12
    Share Outstanding 118
    Price to Book Ratio 0.00
    Return on Assets (%) 4.98
    Return on Capital (%) 5.86
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 152.35
    Total Assets 5756.67
    Total Liabilities 5756.67
    Total Equity 4100.62
    Share Outstanding 99
    Price to Book Ratio 0.00
    Return on Assets (%) 9.92
    Return on Capital (%) 13.4
    Particulars MAR 2025 (Values in Cr)
    Net Income 341.71
    Cash from Operations 1226.66
    Cash from Investing -477.46
    Cash from Financing -440.83
    Net change in Cash -25.99
    Free Cash Flow 1891.04
    Particulars MAR 2024 (Values in Cr)
    Net Income 119.80
    Cash from Operations 1161.38
    Cash from Investing -434.01
    Cash from Financing -422.36
    Net change in Cash 148.17
    Free Cash Flow 1873.42
    Particulars MAR 2023 (Values in Cr)
    Net Income -160.56
    Cash from Operations 672.89
    Cash from Investing -1338.78
    Cash from Financing 817.79
    Net change in Cash -37.10
    Free Cash Flow 1637.63
    Particulars MAR 2022 (Values in Cr)
    Net Income 441.03
    Cash from Operations 935.84
    Cash from Investing -1812.10
    Cash from Financing 794.19
    Net change in Cash -251.49
    Free Cash Flow 1825.35
    Particulars MAR 2021 (Values in Cr)
    Net Income 639.68
    Cash from Operations 742.09
    Cash from Investing -4479.93
    Cash from Financing 3976.83
    Net change in Cash 94.48
    Free Cash Flow 1344.28
    Particulars MAR 2025 (Values in Cr)
    Net Income 911.14
    Cash from Operations 783.06
    Cash from Investing -549.98
    Cash from Financing -61.74
    Net change in Cash -62.95
    Free Cash Flow 1065.84
    Particulars MAR 2024 (Values in Cr)
    Net Income 507.62
    Cash from Operations 436.10
    Cash from Investing -635.52
    Cash from Financing 451.38
    Net change in Cash 174.15
    Free Cash Flow 761.66
    Particulars MAR 2023 (Values in Cr)
    Net Income 123.69
    Cash from Operations 131.55
    Cash from Investing -435.05
    Cash from Financing 290.12
    Net change in Cash -73.41
    Free Cash Flow 376.41
    Particulars MAR 2022 (Values in Cr)
    Net Income 477.41
    Cash from Operations 351.85
    Cash from Investing -1245.61
    Cash from Financing 896.40
    Net change in Cash -100.02
    Free Cash Flow 584.67
    Particulars MAR 2021 (Values in Cr)
    Net Income 349.11
    Cash from Operations 130.01
    Cash from Investing -4382.89
    Cash from Financing 4494.16
    Net change in Cash 145.99
    Free Cash Flow 188.12
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.08 12.84 1.50 238.18 23.12 38.85
    BLISS GVS PHARMA LTD 530.35 43.05 4.71 5624.69 118.35 541.75
    CIPLA LTD 1453.50 30.85 3.41 117420.32 1165.55 1672.20
    FERMENTA BIOTECH LIMITED 356.70 15.73 2.58 1049.80 256.40 399.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 31.08 21.73 4.00 238.18 23.12 38.85
    AMRUTAJAN HEALTH LTD 539.05 24.16 4.20 1558.43 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8054.15 105.19 23.07 20135.38 7630.00 9850.00
    BLISS GVS PHARMA LTD 530.35 57.21 4.86 5624.69 118.35 541.75

    PIRAMAL PHARMA LIMITED shareholding pattern

    Holding
    19.35%
    34.85%
    30.17%
    15.61%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    PIRAMAL PHARMA LIMITED Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    168.09 0.82 redarrow
    red-green-graph indicator
    2 Bearish
    14 Bullish
    • 5 Days 166.80
    • 26 Days 166.50
    • 10 Days 166.00
    • 50 Days 165.30
    • 12 Days 166.00
    • 100 Days 165.30
    • 20 Days 166.40
    • 200 Days 172.20
    167.23 PIVOT
    First Support 164.68 First Resistance 169.28 Second Support 162.63 Second Resistance 171.83 Third Support 160.08 Third Resistance 173.88
    RSI 50.36 ADX 14.48 MACD -0.48 Williams % R -51.52 Commodity Channel Index (CCI) 23.41
    Date 2026-06-29 Week 3202085.00 Same Day 1008158.00 Month 1760947.00
    1 Year 1.15 3 Year 0.88
    Over 1 Month
    -3.51% down
    Over 1 Year
    -18.02% down
    Over 3 Months
    22.10% down
    Over 3 Years
    22.68% down
    Over 6 Months
    -3.54% down
    Over 5 Years
    0.00% down

    PIRAMAL PHARMA LIMITED Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    16 Jul 2025 0.14 Final 16 Jul 2025 Equity shares
    12 Jul 2024 0.11 Final 12 Jul 2024 Equity shares
    Dividend date Dividend amount Dividend type Record date Instrument type
    16 Jul 2025 0.14 Final 16 Jul 2025 Equity shares
    12 Jul 2024 0.11 Final 12 Jul 2024 Equity shares

    Top Gainers

    Top Losers

    Piramal Pharma Share Result Highlights

    ParticularsSep 2024 (₹ Cr)Jun 2024 (₹ Cr)Mar 2024 (₹ Cr)Dec 2023 (₹ Cr)Sep 2023 (₹ Cr)
    Revenue1284.391063.201525.301024.14994.24
    Operating Expense1115.06988.301215.82967.58987.13
    Net Profit210.0685.27273.0874.3477.16
    Net Profit Margin (%)16.358.0217.907.257.76
    Earnings Per Share (EPS)1.590.642.060.560.61
    EBITDA359.27188.39442.83158.64175.24
    Effective Tax Rate (%)23.8123.6324.7017.0819.78

    Key Highlights

    • Revenue increased to ₹1284.39 Cr in Sep 2024, significantly higher than ₹1063.20 Cr in Jun 2024.
    • Net Profit saw a sharp rise to ₹210.06 Cr in Sep 2024, compared to ₹85.27 Cr in Jun 2024, showing substantial growth.
    • Net Profit Margin improved to 16.35% in Sep 2024, reflecting better profitability compared to 8.02% in Jun 2024.
    • Earnings Per Share (EPS) rose to ₹1.59 in Sep 2024, a strong improvement over ₹0.64 in Jun 2024.
    • EBITDA was ₹359.27 Cr in Sep 2024, indicating a strong operational performance.

    Piramal Pharma Share Annual Reports

    ParticularsValue (₹ Cr)
    Revenue4390.11
    Operating Expense4084.54
    Net Profit391.22
    Net Profit Margin (%)8.91
    Earnings Per Share (EPS)3.05
    EBITDA819.98
    Effective Tax Rate (%)22.93

    Key Highlights

    • Revenue of ₹4390.11 crore.
    • Operating expense of ₹4084.54 crore.
    • Net profit of ₹391.22 crore.
    • Net profit margin at 8.91%.
    • EPS of ₹3.05.
    • EBITDA of ₹819.98 crore.
    • Effective tax rate of 22.93%.
    • Piramal Pharma share price increased by 117.43% in the past year.

    Piramal Pharma Share Dividend

    ParticularsValue
    Dividend Yield0.04%
    Earnings Per Share (EPS)₹3.05
    Net Profit₹391.22 Cr
    Piramal Pharma Share Price₹273.45

    Key Highlights

    • Dividend yield of 0.04%.
    • EPS of ₹3.05.
    • Net profit of ₹391.22 crore.
    • Piramal Pharma share price at ₹273.45.

    Popular FAQs

    1. Who is the CEO of Piramal Pharma Ltd?

    The CEO of Piramal Pharma Ltd is Nandini Piramal. She is also the Chairperson of Piramal Enterprises Ltd, which is the parent company of Piramal Pharma Ltd. Under her leadership, the company has expanded its offerings in the pharmaceutical sector, including drug discovery, development, and manufacturing services.

     

    2. When was Piramal Pharma Ltd established?

    Piramal Pharma Ltd was incorporated on March 4, 2020, as a public limited company. The company was subsequently registered with the Registrar of Companies (RoC). It came into existence as a part of Piramal Enterprises Ltd's strategic reorganisation, which aimed to demerge its pharmaceutical business and expand its capabilities in drug manufacturing, biologics, vaccines, and self-care products.

     

    3. What factors influence the Piramal Pharma Share Price?

    The Piramal Pharma share price is influenced by various factors, including the company’s financial performance, industry growth, and global demand for pharmaceutical products. Key drivers include the company’s expansion into biologics and vaccines, joint ventures with companies like Allergan (now AbbVie), and the launch of new products. Other factors such as regulatory changes, competition in the pharmaceutical industry, and global market conditions also impact the Piramal Pharma share price.

     

    4. Is Piramal Pharma Ltd debt-free?

    No, Piramal Pharma Ltd is not debt-free. The company has undertaken strategic acquisitions and investments, which sometimes involve debt financing. However, Piramal Pharma has a strong portfolio of differentiated products and services, a global manufacturing footprint, and an expanding distribution network that support its ability to manage and service its debt.

     

    5. What is the CAGR of Piramal Pharma Share?

    The Compound Annual Growth Rate (CAGR) of the Piramal Pharma share price is not readily available for 10 years and 5 years. However, the share price has performed well over the past year, with a notable increase of 117%. This growth is indicative of the company’s positive trajectory, particularly following the demerger from Piramal Enterprises Ltd and its strategic investments and acquisitions.

     

    6. How has the Piramal Pharma Share Price performed over the past year?

    The Piramal Pharma share price has performed exceptionally well over the past year, with a significant increase of 117%. This growth can be attributed to the company's strategic initiatives, including the expansion of its product offerings, the successful demerger from Piramal Enterprises, and its continued expansion into high-demand sectors such as biologics and vaccines. The company has also strengthened its global presence, which has positively impacted investor confidence and share price performance.

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Piramal Pharma Ltd?

    Answer Field

    Piramal Pharma Ltd share price is for NSE ₹ 168.58 & for BSE ₹ 168.65 as on Jul 01 2026 10:19 AM.

    What is the Market Cap of Piramal Pharma Ltd Share?

    Answer Field

    The market cap of Piramal Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 01 2026 10:19 AM.

    What is the 52 Week High and Low of Piramal Pharma Ltd?

    Answer Field

    The 52 Week High and Low of Piramal Pharma Ltd for NSE is ₹ 220.85 and ₹ 132.30 and for BSE is ₹ 220.90 and ₹ 132.50.

    What is 1 year return for Piramal Pharma Ltd?

    Answer Field

    The 1 year returns on the stock has been -18.02%.

    What is the P/E Ratio of Piramal Pharma Ltd Share?

    Answer Field

    As on Jul 01 2026 10:19 AM the price-to-earnings (PE) ratio for Piramal Pharma Ltd share is 31.68.

    What is the PB ratio of Piramal Pharma Ltd Share?

    Answer Field

    As on Jul 01 2026 10:19 AM, the price-to-book (PB) ratio for Piramal Pharma Ltd share is 61.18.

    How to Buy Piramal Pharma Ltd Share?

    Answer Field

    You can trade in Piramal Pharma Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Piramal Pharma Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Piramal Pharma Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Piramal Pharma Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    Who is the CEO of Piramal Pharma Ltd?

    Answer Field

    The CEO of Piramal Pharma Ltd is Nandini Piramal. She is also the Chairperson of Piramal Enterprises Ltd, which is the parent company of Piramal Pharma Ltd. Under her leadership, the company has expanded its offerings in the pharmaceutical sector, including drug discovery, development, and manufacturing services.

    When was Piramal Pharma Ltd established?

    Answer Field

    Piramal Pharma Ltd was incorporated on March 4, 2020, as a public limited company. The company was subsequently registered with the Registrar of Companies (RoC). It came into existence as a part of Piramal Enterprises Ltd's strategic reorganisation, which aimed to demerge its pharmaceutical business and expand its capabilities in drug manufacturing, biologics, vaccines, and self-care products.

    What factors influence the Piramal Pharma Share Price?

    Answer Field

    The Piramal Pharma share price is influenced by various factors, including the company’s financial performance, industry growth, and global demand for pharmaceutical products. Key drivers include the company’s expansion into biologics and vaccines, joint ventures with companies like Allergan (now AbbVie), and the launch of new products. Other factors such as regulatory changes, competition in the pharmaceutical industry, and global market conditions also impact the Piramal Pharma share price.

    Is Piramal Pharma Ltd debt-free?

    Answer Field

    No, Piramal Pharma Ltd is not debt-free. The company has undertaken strategic acquisitions and investments, which sometimes involve debt financing. However, Piramal Pharma has a strong portfolio of differentiated products and services, a global manufacturing footprint, and an expanding distribution network that support its ability to manage and service its debt.

    What is the CAGR of Piramal Pharma Share?

    Answer Field

    The Compound Annual Growth Rate (CAGR) of the Piramal Pharma share price is not readily available for 10 years and 5 years. However, the share price has performed well over the past year, with a notable increase of 117%. This growth is indicative of the company’s positive trajectory, particularly following the demerger from Piramal Enterprises Ltd and its strategic investments and acquisitions.

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |